Free Trial
→ URGENT: This Altcoin Opportunity Won’t Wait – Act Now (From Crypto Swap Profits) (Ad) Buy AURA Stock  Free AURA Stock Alerts

Aura Biosciences (AURA) Financials

Aura Biosciences logo
$5.48 -0.44 (-7.42%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$6.54 +1.06 (+19.41%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Aura Biosciences

Annual Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -59 -76 -87
Consolidated Net Income / (Loss)		 -59 -76 -87
Net Income / (Loss) Continuing Operations		 -59 -76 -87
Total Pre-Tax Income 		-59 -76 -87
Total Operating Income		 -60 -85 -96
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 60 85 96
Selling, General & Admin Expense		 18 20 23
Research & Development Expense		 42 65 73
Total Other Income / (Expense), net		 1.53 8.72 9.31
Interest Expense		 -1.86 -8.59 -9.43
Other Income / (Expense), net		 -0.33 0.13 -0.12
Income Tax Expense		 0.00 0.14 0.11
Basic Earnings per Share		 ($1.96) ($1.93) ($1.75)
Weighted Average Basic Shares Outstanding		 29.94M 39.62M 49.65M
Diluted Earnings per Share		 ($1.96) ($1.93) ($1.75)
Weighted Average Diluted Shares Outstanding		 29.94M 39.62M 49.65M
Weighted Average Basic & Diluted Shares Outstanding		 37.80M 49.50M 50.23M

Quarterly Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -16 -17 -17 -18 -19 -22 -20 -20 -21 -26
Consolidated Net Income / (Loss)		 -16 -17 -17 -18 -19 -22 -20 -20 -21 -26
Net Income / (Loss) Continuing Operations		 -16 -17 -17 -18 -19 -22 -20 -20 -21 -26
Total Pre-Tax Income 		-16 -17 -17 -18 -19 -22 -20 -20 -21 -26
Total Operating Income		 -16 -18 -19 -20 -20 -25 -22 -23 -23 -28
Total Operating Expenses		 16 18 19 20 20 25 22 23 23 28
Selling, General & Admin Expense		 4.76 4.45 5.04 5.16 5.06 4.50 5.26 5.88 6.20 5.47
Research & Development Expense		 11 13 14 15 15 20 17 17 17 22
Total Other Income / (Expense), net		 0.15 1.05 1.98 1.98 1.98 2.79 2.65 2.43 2.23 2.00
Interest Expense		 -0.48 -1.06 -1.99 -2.01 -1.98 -2.61 -2.69 -2.45 -2.26 -2.04
Other Income / (Expense), net		 -0.33 -0.01 -0.01 -0.03 -0.01 0.18 -0.03 -0.03 -0.03 -0.04
Income Tax Expense		 - - 0.00 0.00 0.00 0.14 0.05 0.00 0.04 0.02
Basic Earnings per Share		 ($0.54) ($0.52) ($0.46) ($0.48) ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52)
Weighted Average Basic Shares Outstanding		 29.27M 29.94M 37.78M 37.86M 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M
Diluted Earnings per Share		 ($0.54) ($0.52) ($0.46) ($0.48) ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52)
Weighted Average Diluted Shares Outstanding		 29.27M 29.94M 37.78M 37.86M 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M
Weighted Average Basic & Diluted Shares Outstanding		 29.33M 37.80M 37.80M 38.20M 38.26M 49.50M 49.54M 49.61M 49.95M 50.23M

Annual Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -27 -81 -9.39
Net Cash From Operating Activities		 -55 -64 -80
Net Cash From Continuing Operating Activities		 -55 -64 -80
Net Income / (Loss) Continuing Operations		 -59 -76 -87
Consolidated Net Income / (Loss)		 -59 -76 -87
Depreciation Expense		 1.18 1.30 1.22
Non-Cash Adjustments To Reconcile Net Income		 6.09 6.83 8.54
Changes in Operating Assets and Liabilities, net		 -3.10 4.44 -2.65
Net Cash From Investing Activities		 -68 -114 69
Net Cash From Continuing Investing Activities		 -68 -114 69
Purchase of Property, Plant & Equipment		 -1.09 -0.71 -1.25
Purchase of Investments		 -120 -234 -59
Sale and/or Maturity of Investments		 53 120 129
Net Cash From Financing Activities		 96 97 1.60
Net Cash From Continuing Financing Activities		 96 97 1.60
Issuance of Common Equity		 95 96 0.18
Other Financing Activities, net		 0.43 1.38 1.42

Quarterly Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 7.29 60 -83 9.24 7.85 -15 -15 3.80 -4.67 6.29
Net Cash From Operating Activities		 -11 -18 -16 -15 -15 -17 -24 -16 -15 -24
Net Cash From Continuing Operating Activities		 -11 -17 -16 -15 -15 -17 -24 -16 -15 -24
Net Income / (Loss) Continuing Operations		 -16 -17 -17 -18 -19 -22 -20 -20 -21 -26
Consolidated Net Income / (Loss)		 -16 -17 -17 -18 -19 -22 -20 -20 -21 -26
Depreciation Expense		 0.30 0.32 0.33 0.30 0.34 0.32 0.31 0.31 0.31 0.29
Non-Cash Adjustments To Reconcile Net Income		 1.72 1.20 1.02 1.21 2.20 2.39 1.52 2.41 2.08 2.53
Changes in Operating Assets and Liabilities, net		 2.46 -2.45 -0.30 1.89 0.81 2.03 -6.57 1.49 3.38 -0.94
Net Cash From Investing Activities		 18 -17 -67 21 22 -90 9.40 20 9.89 30
Net Cash From Continuing Investing Activities		 18 -17 -67 21 22 -90 9.27 20 9.89 30
Purchase of Property, Plant & Equipment		 -0.06 -0.36 -0.12 -0.18 -0.09 -0.32 -0.21 -0.40 -0.34 -0.30
Sale and/or Maturity of Investments		 18 32 22 22 22 55 39 30 30 30
Net Cash From Financing Activities		 0.10 95 0.20 2.48 1.63 93 0.25 0.08 0.72 0.54
Net Cash From Continuing Financing Activities		 0.10 95 0.20 2.48 1.63 93 0.25 0.08 0.72 0.54
Other Financing Activities, net		 0.10 - 0.15 0.66 0.20 0.37 0.16 0.08 0.63 0.54

Annual Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 224 255 183
Total Current Assets		 197 232 161
Cash & Equivalents		 122 41 32
Restricted Cash		 0.02 0.02 0.00
Short-Term Investments		 67 185 119
Prepaid Expenses		 7.87 5.63 9.53
Plant, Property, & Equipment, net		 5.37 3.15 3.22
Total Noncurrent Assets		 22 20 19
Other Noncurrent Operating Assets		 21 19 18
Other Noncurrent Nonoperating Assets		 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 224 255 183
Total Liabilities		 28 29 31
Total Current Liabilities		 10 12 15
Accounts Payable		 2.92 1.79 2.30
Accrued Expenses		 4.57 7.88 9.46
Other Current Liabilities		 2.96 2.69 3.15
Total Noncurrent Liabilities		 18 17 16
Other Noncurrent Operating Liabilities		 18 17 16
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 196 226 152
Total Preferred & Common Equity		 196 226 152
Total Common Equity		 196 226 152
Common Stock		 407 513 526
Retained Earnings		 -211 -287 -374
Accumulated Other Comprehensive Income / (Loss)		 -0.07 0.54 0.26

Quarterly Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 143 206 193 180 235 218 205
Total Current Assets		 116 179 166 154 212 196 183
Cash & Equivalents		 61 38 48 56 26 30 25
Restricted Cash		 0.18 0.02 0.02 0.02 0.00 0.00 0.00
Short-Term Investments		 50 135 114 93 177 157 149
Prepaid Expenses		 4.21 5.58 4.18 4.81 9.38 8.18 9.10
Plant, Property, & Equipment, net		 5.48 5.17 5.06 4.86 3.05 3.33 3.33
Total Noncurrent Assets		 22 22 21 21 20 19 19
Other Noncurrent Operating Assets		 21 21 21 20 19 19 18
Other Noncurrent Nonoperating Assets		 0.77 0.77 0.77 0.77 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 143 206 193 180 235 218 205
Total Liabilities		 28 26 26 28 26 27 31
Total Current Liabilities		 9.96 8.11 8.90 11 9.66 11 15
Accounts Payable		 1.72 1.06 0.55 1.49 1.93 1.46 1.99
Accrued Expenses		 5.30 4.07 5.33 6.37 4.99 6.34 9.60
Other Current Liabilities		 2.94 2.99 3.01 3.04 2.74 2.75 3.13
Total Noncurrent Liabilities		 18 18 17 17 17 16 16
Other Noncurrent Operating Liabilities		 18 18 17 17 17 16 16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 115 180 166 152 209 191 175
Total Preferred & Common Equity		 115 180 166 152 209 191 175
Total Common Equity		 115 180 166 152 209 191 175
Common Stock		 310 409 413 417 516 519 522
Retained Earnings		 -194 -228 -247 -265 -307 -327 -348
Accumulated Other Comprehensive Income / (Loss)		 -0.15 -0.05 -0.22 -0.13 0.02 -0.18 0.61

Annual Metrics and Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -72.71% -40.56% -13.70%
EBIT Growth		 -71.98% -39.97% -13.41%
NOPAT Growth		 -71.05% -40.96% -13.09%
Net Income Growth		 -66.70% -30.03% -13.76%
EPS Growth		 78.10% 1.53% 9.33%
Operating Cash Flow Growth		 -68.47% -16.93% -24.99%
Free Cash Flow Firm Growth		 -74.06% -16.27% -30.63%
Invested Capital Growth		 92.78% -118.20% 109.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -24.84% -9.11% -3.57%
EBIT Q/Q Growth		 -24.48% -8.96% -3.49%
NOPAT Q/Q Growth		 -24.63% -9.21% -3.25%
Net Income Q/Q Growth		 -9.15% -7.87% -4.45%
EPS Q/Q Growth		 -102.92% 0.52% -0.57%
Operating Cash Flow Q/Q Growth		 -12.18% 0.97% -8.96%
Free Cash Flow Firm Q/Q Growth		 0.00% 2.50% -9.02%
Invested Capital Q/Q Growth		 131.49% -158.11% 122.64%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.18% 100.13%
Interest Burden Percent		 96.93% 89.88% 90.20%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -33.78% -36.26% -46.01%
Cash Return on Invested Capital (CROIC)		 -992.22% 0.00% -63,405.74%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -33.78% -36.26% -46.01%
Return on Equity Simple (ROE_SIMPLE)		 -30.05% -33.83% -57.19%
Net Operating Profit after Tax (NOPAT)		 -42 -59 -67
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -9.77% -8.12% -10.37%
Return On Investment Capital (ROIC_SIMPLE)		 - -26.34% -44.27%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -61 -85 -96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -59 -84 -95
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.57 1.50 2.70
Price to Tangible Book Value (P/TBV)		 1.57 1.50 2.70
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 19.92 0.00 2,402.84
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.99 -1.00
Leverage Ratio		 1.10 1.14 1.16
Compound Leverage Factor		 1.07 1.02 1.04
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 5.30 5.32 4.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 18.81 18.76 10.77
Quick Ratio		 18.06 18.30 10.13
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -45 -52 -68
Operating Cash Flow to CapEx		 -4,990.95% -9,005.22% -6,369.11%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 5.98 -1.09 0.11
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.88 -7.07 1.20
Enterprise Value (EV)		 119 113 260
Market Capitalization		 308 339 411
Book Value per Share		 $6.67 $5.90 $3.04
Tangible Book Value per Share		 $6.67 $5.90 $3.04
Total Capital		 196 226 152
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -189 -226 -151
Capital Expenditures (CapEx)		 1.09 0.71 1.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.59 -6.73 -5.38
Debt-free Net Working Capital (DFNWC)		 186 219 146
Net Working Capital (NWC)		 186 219 146
Net Nonoperating Expense (NNE)		 17 17 20
Net Nonoperating Obligations (NNO)		 -190 -227 -152
Total Depreciation and Amortization (D&A)		 1.18 1.30 1.22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($1.96) ($1.93) ($1.75)
Adjusted Weighted Average Basic Shares Outstanding		 29.94M 39.62M 49.65M
Adjusted Diluted Earnings per Share		 ($1.96) ($1.93) ($1.75)
Adjusted Weighted Average Diluted Shares Outstanding		 29.94M 39.62M 49.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 37.80M 49.50M 50.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -42 -59 -67
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -86.41% -216.21% -51.77% -48.60% -25.30% -40.33% -15.21% -12.33% -13.87% -13.50%
EBIT Growth		 -85.28% -209.12% -51.30% -47.59% -25.08% -39.60% -14.84% -12.21% -13.49% -13.19%
NOPAT Growth		 -80.49% -209.16% -51.78% -46.76% -27.61% -40.71% -14.76% -12.26% -13.39% -12.21%
Net Income Growth		 -79.92% -42.33% -36.08% -35.87% -16.42% -33.65% -12.82% -11.14% -13.67% -16.73%
EPS Growth		 98.09% -100.76% -4.55% -4.35% 11.11% 1.92% 13.04% 14.58% 12.50% -1.96%
Operating Cash Flow Growth		 -23.82% -49.04% -7.97% -37.80% -43.15% 3.48% -48.99% -10.13% 0.84% -37.76%
Free Cash Flow Firm Growth		 -34.74% 0.00% 28.41% 24.95% -18.44% 32.44% -24.45% -32.04% -2.06% -101.10%
Invested Capital Growth		 11.66% 92.78% -22.32% -39.79% -27.50% -118.20% -13.57% -10.07% -125.45% 109.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -19.44% -7.57% -10.57% -4.60% -0.71% -20.48% 9.22% -1.98% -2.09% -20.10%
EBIT Q/Q Growth		 -19.07% -7.56% -10.41% -4.37% -0.91% -20.05% 9.17% -1.98% -2.06% -19.73%
NOPAT Q/Q Growth		 -16.21% -9.70% -10.40% -4.28% -1.05% -20.96% 9.97% -2.01% -2.06% -19.70%
Net Income Q/Q Growth		 -18.07% -4.14% -5.48% -4.77% -1.16% -19.55% 10.96% -3.20% -3.47% -22.77%
EPS Q/Q Growth		 -17.39% 3.70% 11.54% -4.35% 0.00% -6.25% 21.57% -2.50% -2.44% -23.81%
Operating Cash Flow Q/Q Growth		 -1.24% -67.41% 8.89% 10.77% -5.18% -12.88% -40.63% 34.04% 5.30% -56.83%
Free Cash Flow Firm Q/Q Growth		 26.75% -32.16% 21.75% 0.94% -15.61% 24.62% -44.16% -5.10% 10.64% -48.54%
Invested Capital Q/Q Growth		 -57.19% 131.49% -0.60% -38.87% -48.46% -158.11% 572.08% -36.39% -114.59% 122.64%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.62% 100.23% 100.00% 100.20% 100.09%
Interest Burden Percent		 97.05% 93.96% 89.77% 90.11% 90.33% 89.40% 87.98% 89.24% 90.29% 92.69%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.02% -33.78% -39.46% -46.17% -53.11% -36.26% -40.43% -45.09% -50.99% -46.01%
Cash Return on Invested Capital (CROIC)		 0.00% -992.22% -663.59% -1,012.27% -2,411.47% 0.00% -1,094.69% -1,820.92% 0.00% -63,405.74%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 4.32% -33.78% -39.46% -46.17% -53.11% -36.26% -40.43% -45.09% -50.99% -46.01%
Return on Equity Simple (ROE_SIMPLE)		 -46.79% 0.00% -35.17% -40.99% -46.69% 0.00% -37.67% -42.14% -47.64% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -12 -14 -14 -14 -17 -16 -16 -16 -19
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.80% -2.50% -2.51% -2.87% -3.18% -2.30% -2.16% -2.51% -2.94% -3.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -7.68% - - - -12.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -18 -19 -20 -20 -25 -22 -23 -23 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -17 -19 -20 -20 -24 -22 -22 -23 -28
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.61 1.57 1.95 2.80 2.26 1.50 1.86 1.96 2.53 2.70
Price to Tangible Book Value (P/TBV)		 4.61 1.57 1.95 2.80 2.26 1.50 1.86 1.96 2.53 2.70
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 161.99 19.92 29.80 83.83 103.28 0.00 36.13 57.23 0.00 2,402.84
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.97 -0.96 -0.97 -0.98 -0.99 -0.97 -0.98 -1.00 -1.00
Leverage Ratio		 1.17 1.10 1.10 1.11 1.21 1.14 1.13 1.15 1.18 1.16
Compound Leverage Factor		 1.14 1.04 0.98 1.00 1.09 1.02 1.00 1.02 1.07 1.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.94 5.94 7.30 9.49 5.84 6.10 7.78 6.95 6.88 5.65
Noncontrolling Interest Sharing Ratio		 108.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 11.63 18.81 22.09 18.69 14.13 18.76 21.97 18.54 12.47 10.77
Quick Ratio		 11.19 18.06 21.40 18.21 13.68 18.30 20.99 17.77 11.85 10.13
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -15 -12 -12 -14 -10 -15 -16 -14 -21
Operating Cash Flow to CapEx		 -17,079.37% -5,031.56% -13,235.48% -8,227.53% -17,114.44% -5,484.86% -11,643.81% -4,001.99% -4,478.89% -8,010.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 2.59 5.98 5.95 3.64 1.87 -1.09 5.14 3.27 -0.48 0.11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.27 2.88 -1.71 -2.40 -0.71 -7.07 -0.81 -0.37 -2.35 1.20
Enterprise Value (EV)		 419 119 177 305 194 113 186 187 268 260
Market Capitalization		 530 308 351 467 343 339 389 375 442 411
Book Value per Share		 $3.93 $6.67 $4.77 $4.40 $3.97 $5.90 $4.22 $3.86 $3.52 $3.04
Tangible Book Value per Share		 $3.93 $6.67 $4.77 $4.40 $3.97 $5.90 $4.22 $3.86 $3.52 $3.04
Total Capital		 115 196 180 166 152 226 209 191 175 152
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -112 -189 -174 -162 -149 -226 -203 -187 -174 -151
Capital Expenditures (CapEx)		 0.06 0.36 0.12 0.18 0.09 0.32 0.21 0.40 0.34 0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.76 -2.59 -2.53 -4.72 -6.08 -6.73 -0.29 -2.37 -5.61 -5.38
Debt-free Net Working Capital (DFNWC)		 106 186 171 157 143 219 203 185 169 146
Net Working Capital (NWC)		 106 186 171 157 143 219 203 185 169 146
Net Nonoperating Expense (NNE)		 4.66 4.23 3.86 4.11 4.17 4.78 4.09 4.40 4.78 6.37
Net Nonoperating Obligations (NNO)		 -112 -190 -174 -163 -150 -227 -204 -188 -175 -152
Total Depreciation and Amortization (D&A)		 0.30 0.32 0.33 0.30 0.34 0.32 0.31 0.31 0.31 0.29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.54) ($0.52) ($0.46) ($0.48) ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 29.27M 29.94M 37.78M 37.86M 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M
Adjusted Diluted Earnings per Share		 ($0.54) ($0.52) ($0.46) ($0.48) ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 29.27M 29.94M 37.78M 37.86M 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 29.33M 37.80M 37.80M 38.20M 38.26M 49.50M 49.54M 49.61M 49.95M 50.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -12 -14 -14 -14 -17 -16 -16 -16 -19
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Aura Biosciences' Financials

When does Aura Biosciences's fiscal year end?

According to the most recent income statement we have on file, Aura Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Aura Biosciences' net income changed over the last 2 years?

Aura Biosciences' net income appears to be on an upward trend, with a most recent value of -$86.92 million in 2024, rising from -$58.76 million in 2022. The previous period was -$76.41 million in 2023. See Aura Biosciences' forecast for analyst expectations on what’s next for the company.

What is Aura Biosciences's operating income?
Aura Biosciences's total operating income in 2024 was -$96.12 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $96.12 million
How has Aura Biosciences revenue changed over the last 2 years?

Over the last 2 years, Aura Biosciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Aura Biosciences have?

Aura Biosciences' total liabilities were at $30.53 million at the end of 2024, a 4.5% increase from 2023, and a 7.7% increase since 2022.

How much cash does Aura Biosciences have?

In the past 2 years, Aura Biosciences' cash and equivalents has ranged from $31.69 million in 2024 to $121.58 million in 2022, and is currently $31.69 million as of their latest financial filing in 2024.

How has Aura Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Aura Biosciences' book value per share changed from 6.67 in 2022 to 3.04 in 2024, a change of -54.4%.


Related Companies

This page (NASDAQ:AURA) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored